Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients

被引：0

作者：

Mantsiou, Chrysanthi ^{[1
]}

Tziomalos, Konstantinos ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Med Sch, Propedeut Dept Internal Med 1, Thessaloniki, Greece

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2018年 / 34卷 / 10期

关键词：

Atorvastatin; rosuvastatin; ezetimibe; PCSK9; inhibitors; low-density lipoprotein cholesterol targets; INTENSITY STATIN THERAPY; PCSK9; INHIBITORS; ATORVASTATIN; CORONARY; METAANALYSIS; PREVENTION; GUIDELINES; EZETIMIBE; DISEASE; STROKE;

D O I：

10.1080/03007995.2018.1510224

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several options exist in very-high risk patients who do not achieve low-density lipoprotein cholesterol (LDL-C) targets despite treatment with atorvastatin 80 mg, including switching to rosuvastatin 40 mg, adding ezetimibe or adding a proprotein convertase subtilisin/kexin type 9 inhibitor. Taking into account the safety, LDL-C lowering capacity, effect on cardiovascular events and cost of these available options, switching to rosuvastatin 40 mg appears to represent the most attractive strategy. Nevertheless, more studies are needed to confirm the effects of this strategy on LDL-C levels given the limited available data.

引用

页码：1713 / 1715

页数：3

共 23 条

[1]

Amarenco P, 2006, NEW ENGL J MED, V355, P549

[2] Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial [J].

Arrieta, Alejandro ;

Hong, Jonathan C. ;

Khera, Rohan ;

Virani, Salim S. ;

Krumholz, Harlan M. ;

Nasir, Khurram .

JAMA CARDIOLOGY, 2017, 2 (12) :1369-1374

[3] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes [J].

Cannon, Christopher P. ;

Blazing, Michael A. ;

Giugliano, Robert P. ;

McCagg, Amy ;

White, Jennifer A. ;

Theroux, Pierre ;

Darius, Harald ;

Lewis, Basil S. ;

Ophuis, Ton Oude ;

Jukema, J. Wouter ;

De Ferrari, Gaetano M. ;

Ruzyllo, Witold ;

De Lucca, Paul ;

Im, KyungAh ;

Bohula, Erin A. ;

Reist, Craig ;

Wiviott, Stephen D. ;

Tershakovec, Andrew M. ;

Musliner, Thomas A. ;

Braunwald, Eugene ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) :2387-2397

[4] 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].

Catapano, Alberico L. ;

Graham, Ian ;

De Backer, Guy ;

Wiklund, Olov ;

Chapman, M. John ;

Drexel, Heinz ;

Hoes, Arno W. ;

Jennings, Catriona S. ;

Landmesser, Ulf ;

Pedersen, Terje R. ;

Reiner, Zeljko ;

Riccardi, Gabriele ;

Taskinen, Marja-Riita ;

Tokgozoglu, Lale ;

Verschuren, W. M. Monique ;

Vlachopoulos, Charalambos ;

Wood, David A. ;

Luis Zamorano, Jose .

ATHEROSCLEROSIS, 2016, 253 :281-344

[5] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].

Colhoun, HM ;

Betteridge, DJ ;

Durrington, PN ;

Hitman, GA ;

Neil, HAW ;

Livingstone, SJ ;

Thomason, MJ ;

Mackness, MI ;

Charlton-Menys, V ;

Fuller, JH .

LANCET, 2004, 364 (9435) :685-696

[6] To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis [J].

Karlson, Bjorn W. ;

Palmer, Michael K. ;

Nicholls, Stephen J. ;

Lundman, Pia ;

Barter, Philip J. .

ATHEROSCLEROSIS, 2015, 241 (02) :450-454

[7] 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia [J].

Landmesser, Ulf ;

Chapman, M. John ;

Stock, Jane K. ;

Amarenco, Pierre ;

Belch, Jill J. F. ;

Boren, Jan ;

Farnier, Michel ;

Ference, Brian A. ;

Gielen, Stephan ;

Graham, Ian .

EUROPEAN HEART JOURNAL, 2018, 39 (14) :1131-1143

[8] Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J].

LaRosa, JC ;

Grundy, SM ;

Waters, DD ;

Shear, C ;

Barter, P ;

Fruchart, J ;

Gotto, AM ;

Greten, H ;

Kastelein, JJP ;

Shepherd, J ;

Wenger, NK .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) :1425-1435

[9]

Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4

[10] LDL cholesterol levels after switch from atorvastatin to rosuvastatin [J].

Lewis, Sandra J. ;

Olufade, Temitope ;

Anzalone, Deborah A. ;

Malangone-Monaco, Elisabetta ;

Evans, Kristin A. ;

Johnston, Stephen .

CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) :1717-1723

← 1 2 3 →